Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Stock Report

Market Cap: US$7.7b

Cerevel Therapeutics Holdings Management

Management criteria checks 2/4

Cerevel Therapeutics Holdings' CEO is Ron Renaud, appointed in Jun 2023, has a tenure of less than a year. directly owns 0.13% of the company’s shares, worth $10.31M. The average tenure of the management team and the board of directors is 3.3 years and 5 years respectively.

Key information

Ron Renaud

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.1%
Management average tenure3.3yrs
Board average tenure5yrs

Recent management updates

Recent updates

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Aug 12

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Aug 01

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease

Oct 30

CEO

Ron Renaud (54 yo)

less than a year

Tenure

Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...


Leadership Team

NamePositionTenureCompensationOwnership
N. Coles
Executive Chairman5.3yrsUS$11.23m0.0086%
$ 659.6k
Mark Bodenrader
VP of Finance & Chief Accounting Officer4.5yrsUS$1.58m0.0098%
$ 747.7k
John Renger
Chief Scientific Officer4.9yrsUS$4.78m0.0035%
$ 268.9k
Ramiro Sanchez
Chief Medical Officer5.2yrsUS$4.81m0.0081%
$ 619.0k
Ronald Renaud
Presidentless than a yearno data0.13%
$ 10.3m
Susan Altschuller
Chief Financial Officerless than a yearno data0.0093%
$ 713.2k
Matthew Calistri
Vice President of Investor Relationsno datano datano data
Scott Akamine
Chief Legal Officer & Corporate Secretary2.8yrsUS$3.19m0.0040%
$ 305.7k
Kenneth DiPietro
Chief Human Resources Officer4.9yrsno data0.014%
$ 1.0m
Kathleen Tregoning
Chief Corporate Affairs Officer3.7yrsUS$3.92m0.0059%
$ 449.7k
Paul Burgess
Chief Business Development & Strategic Operations Officerless than a yearno data0.025%
$ 1.9m

3.3yrs

Average Tenure

53yo

Average Age

Experienced Management: CERE's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
N. Coles
Executive Chairman5.3yrsUS$11.23m0.0086%
$ 659.6k
Ronald Renaud
Presidentless than a yearno data0.13%
$ 10.3m
Gabrielle Greene-Sulzberger
Independent Director4.8yrsUS$510.98k0.025%
$ 1.9m
Marijn Dekkers
Independent Director5.5yrsUS$499.32k0.016%
$ 1.2m
Deval Patrick
Independent Director3.2yrsUS$485.48k0%
$ 0
Norbert Riedel
Lead Independent Director5.3yrsUS$562.57k0.024%
$ 1.8m
Christopher Gordon
Independent Director5.5yrsUS$497.15k0%
$ 0
Adam Koppel
Independent Director5.5yrsUS$492.98k0%
$ 0
Douglas Giordano
Independent Director5.5yrsUS$497.15k0%
$ 0
Ruth McKernan
Independent Director3.3yrsUS$485.48k0%
$ 0
Suneet Varma
Independent Director1.8yrsno datano data
Deborah Baron
Independent Director3.2yrsno datano data

5.0yrs

Average Tenure

63yo

Average Age

Experienced Board: CERE's board of directors are considered experienced (5 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.